Notice of General Meeting

Oslo, Norway, 20 April 2005. Please find enclosed an invitation to the annual general meeting at PhotoCure ASA on 3 May 2005, attendance slip and annual report 2004 in English.
 
The attachments are available on the following links:
 
Invitation: http://hugin.info/131151/R/990159/148773.pdf
Attendance slip: http://hugin.info/131151/R/990151/148766.pdf
Annual report: http://hugin.info/131151/R/990152/148767.pdf  
   
PhotoCure ASA is a Norwegian pharmaceutical company founded in 1993 and listed on Oslo Stock Exchange. The company develops and sells pharmaceuticals and medical devices based on proprietary photodynamic technologies, targeting key dermatology and oncology markets.

PhotoCure has two products with sales and marketing approvals: Metvix®, which is a product developed for the treatment of skin cancer (basal cell carcinoma) and pre-cancerous skin lesions (actinic keratosis), and Hexvix®, which is developed for the detection of bladder cancer. Both products are based on the same photodynamic technology, combining the drug known as a photosensitiser with a light source that activates the photosensitiser. PhotoCure is currently testing both products for new indications and aims to develop a pipeline of follow-on products and technologies.

PhotoCure, the PhotoCure logo, Metvix and Hexvix are trademarks or registered trademarks of PhotoCure ASA.

For further information, contact:

PhotoCure ASA
Attn. Kjetil Hestdal (President and CEO) or Christian Fekete (CFO)
Hoffsveien 48
NO-0377 Oslo, Norway

www.photocure.com

Telephone: +47 22 06 22 10
Fax: +47 22 06 22 18

Kjetil Hestdal (kh@photocure.no)
Mobile: +47 913 19 535

Christian Fekete (cf@photocure.no)
Mobile: +47 916 42 938